<DOC>
	<DOCNO>NCT00438152</DOCNO>
	<brief_summary>This study compare benefit patient switch Kaletra® Invirase® tablets remain Kaletra® ( base randomization ) , elicit lipid benefit infer previous study</brief_summary>
	<brief_title>Lopinavir Capsules Kaletra Invirase Tablets</brief_title>
	<detailed_description>This prospective , phase IV , multicentre , randomise , open-label , 2-arm , 24-week study . Approximately 130 HIV-1 infected patient stable antiretroviral regimen contain Kaletra® 2 nucleoside/nucleotide analogue randomize 1 2 treatment arm : saquinavir ritonavir 1000/100 mg BID ( use Invirase® tablet ) lopinavir/ritonavir 400/100 mg BID ( use Kaletra® tablet ) .Eligibility enrollment determine screen visit occur within 30 day baseline visit . Protocol-defined study assessment take place clinic visit end Weeks 4 , 12 , 24 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Male nonpregnant , nonnursing female &gt; 18 year age Seropositive HIV1 On antiretroviral combination Kaletra® 2 nucleoside/nucleotide analogue least 6 month HIV1 RNA viral load &lt; 50 copies/mL ( 2 consecutive measurement prior 6 month ) plus screen viral load &lt; 50 copies/ml . Ability willingness provide write informed consent adhere study regimen Females childbearing potential must document negative serum urine pregnancy test screening/baseline ensure 2 reliable form contraception use , include barrier method , duration study 90 day last dose study medication Documented virological failure protease inhibitor ARV regimen prior commence Kaletra® regimen Documented protease mutation ( one follow list ) prior commence Kaletra® regimen : M46I/L/V , I47A/V , G48V/M , I50V , F53L/Y , I54L/M/V/A/T/S , V82A/T/S/F/M/L , I84A/V/C , L90M Patients acute hepatitis B C infection Females pregnant , breastfeeding , plan become pregnant breastfeed study· Significant renal dysfunction ( creatinine clearance [ CrCl ] &lt; 60 mL/min ) and/or hepatic impairment ( aspartate aminotransferase/alanine aminotransferase [ AST/ALT ] &gt; 3 X ULN and/or document liver cirrhosis ) Note : The site calculate patient 's CrCl use CockcroftGault formula [ 28 ] show : CrCl = [ 140 age ( yr ) ] × weight ( kg ) × constant 72 × serum creatinine ( Cr ) ( mg/dL ) , constant = 1 men 0.85 woman Any current know clinical laboratory parameter ACTG Grade 4 ( see Appendix 4 ) . However , asymptomatic Grade 4 abnormality permit discretion investigator deem clinically appropriate . Abnormalities deem insignificant investigator must discuss sponsor prior enrollment . Evidence active , untreated opportunistic infection , intercurrent illness , drug toxicity condition judgment investigator patient would able take continue prescribe antiretroviral regimen Malignancy require chemotherapy radiotherapy Known hypersensitivity prescribe antiretroviral drug formulation component Evidence alcohol and/or drug substance abuse judgment investigator would likely result patient unreliable fulfilling condition protocol History psychological illness condition judgment investigator might interfere patient 's ability understand requirement study History drug nonadherence judgment investigator would result patient unreliable fulfilling condition protocol Patients receive investigational new drug within last 4 week Currently take , anticipate take course study , drug contraindicate antiretroviral drug randomize receive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>Lopinavir</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Lipids</keyword>
	<keyword>HIV-1</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>